COLL - Collegium Pharmaceutical, Inc.

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD

Collegium Pharmaceutical, Inc.

780 Dedham Street
Suite 800
Canton, MA 02021
United States
781-713-3699
http://www.collegiumpharma.com

SectorHealthcare
SectorDrug Manufacturers - Specialty & Generic
Empleados a tiempo completo250

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Michael T. HeffernanFounder, Chairman, Pres & CEO736kN/A1964
Mr. Paul J. BrannellyExec. VP & CFO452,07kN/A1973
Mr. Joseph J. CiaffoniExec. VP & COON/AN/A1971
Dr. Alison B. FlemingExec. VP & Chief Technology OfficerN/AN/A1975
Ms. Shirley R. KuhlmannExec. VP, Gen. Counsel & Sec.N/AN/A1984
Los importes son a partir de 31 de diciembre de 2016 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving. The company offers Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. It is also developing Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older. In addition, the company offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. Further, it is developing COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of chronic pain; COL-172, an abuse-deterrent, extended-release oxymorphone for the treatment of chronic pain; and COL-171, a proprietary preclinical DETERx extended-release, abuse-deterrent methylphenidate formulation for attention deficit hyperactivity disorder (ADHD), as well as COL-196, a morphine formulation. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Canton, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de Collegium Pharmaceutical, Inc., a día 1 de junio de 2018, es 8. Las puntuaciones base son Auditoría: 2; Tablero: 9; Derechos de los accionistas: 5; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.
Al usar Yahoo aceptas que Yahoo y sus socios puedan utilizar cookies para personalización y otros fines